HDAC inhibitors and RECK modulate endoplasmic reticulum stress in tumor cells

International Journal of Molecular Sciences

Volumn 18, Issue 2, 2017, Pages

  Chen, Yun ^a,b   Tsai, Ya Hui ^a,b   Tseng, Sheng Hong ^c  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b YUAN ZE UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Cancers; Endoplasmic reticulum stress; Histone deacetylase inhibitors; Reversion inducing cysteine rich protein with Kazal motifs

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; ACTIVATING TRANSCRIPTION FACTOR 6; APICIDIN; CASPASE 4; CASPASE 7; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATINASE A; GELATINASE B; GLUCOSE REGULATED PROTEIN 78; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HISTONE DEACETYLASE INHIBITOR; INITIATION FACTOR 2ALPHA; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; RESVERATROL; ROMIDEPSIN; SMALL INTERFERING RNA; VALPROIC ACID; VORINOSTAT; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN;

APOPTOSIS; AUTOPHAGY; BILE DUCT CARCINOMA; BREAST CANCER; CELL INVASION; CELL PROLIFERATION; COLON CANCER; ENDOPLASMIC RETICULUM STRESS; FIBROSARCOMA; GENE EXPRESSION; GLIOMA; HUMAN; IONIZING RADIATION; MULTIPLE MYELOMA; NASOPHARYNX CARCINOMA; NON SMALL CELL LUNG CANCER; OSTEOSARCOMA; REVERSION INDUCING CYSTEINE RICH PROTEIN WITH KAZAL MOTIF; REVIEW; SQUAMOUS CELL CARCINOMA; TRANSLATION INITIATION; TUMOR CELL; TUMOR SUPPRESSOR GENE; UNFOLDED PROTEIN RESPONSE; UPREGULATION; ANIMAL; BIOLOGICAL MODEL; CELL DEATH; DRUG EFFECTS; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; CELL DEATH; ENDOPLASMIC RETICULUM STRESS; GPI-LINKED PROTEINS; HISTONE DEACETYLASE INHIBITORS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 85011101306     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18020258     Document Type: Review

References (49)

1. Clarke, H.J., Chambers, J.E., Liniker, E., Marciniak, S.J. Endoplasmic reticulum stress in malignancy. Cancer Cell 2014, 25, 563-573.
2. Ni, M., Zhang, Y., Lee, A.S. Beyond the endoplasmic reticulum: Atypical GRP78 in cell viability, signaling and therapeutic targeting. Biochem. J. 2011, 434, 181-188.
3. Penaranda Fajardo, N.M., Meijer, C., Kruyt, F.A. The endoplasmic reticulum stress/unfolded protein response in gliomatosis, tumor progression and as a therapeutic target in glioblastoma. Biochem. Pharmacol. 2016, 118, 1-8.
4. Lee, A.S. GRP78 induction in cancer: Therapeutic and prognostic implications. Cancer Res. 2007, 67, 3496-3499.
5. Zhang, L.H., Zhang, X. Roles of GRP78 in physiology and cancer. J. Cell Biochem. 2010, 110, 1299-1305.
6. Li, J., Lee, A.S. Stress induction of GRP78/BiP and its role in cancer. Curr. Mol. Med. 2006, 6, 45-54.
7. Zismanov, V., Drucker, L., Gottfried, M. ER homeostasis and motility of NSCLC cell lines can be therapeutically targeted with combined Hsp90 and HDAC inhibitors. Pulm. Pharmacol. Ther. 2013, 26, 388-394.
8. Dong, D., Ko, B., Baumeister, P., Swenson, S., Costa, F., Markland, F., Stiles, C., Patterson, J.B., Bates, S.E., Lee, A.S. Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 within the tumor microenvironment. Cancer Res. 2005, 65, 5785-5791.
9. Jiang, C.C., Mao, Z.G., Avery-Kiejda, K.A., Wade, M., Hersey, P., Zhang, X.D. Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells. Carcinogenesis 2009, 30, 197-204.
10. Lin, W., Lin, Y., Li, J., Harding, H.P., Ron, D., Jamison, S. A deregulated integrated stress response promotes interferon--induced medulloblastoma. J. Neurosci. Res. 2011, 89, 1586-1595.
11. Ma, Y., Hendershot, L.M. The role of unfolded protein response in tumor development: Friend or foe? Nat. Rev. Cancer 2004, 4, 966-977.
12. Ranganathan, A.C., Zhang, L., Adam, A.P., Aguirre-Ghiso, J.A. Functional coupling of p38-induced upregulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res. 2006, 66, 1702-1711.
13. Rouschop, K.M., van den Beucken, T., Dubois, L., Niessen, H., Bussink, J., Savelkouls, K., Keulers, T., Mujcic, H., Landuyt, W., Voncken, J.W., et al. The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J. Clin. Investig. 2010, 120, 127-141.
14. Romero-Ramirez, L., Cao, H., Nelson, D., Hammond, E., Lee, A.H., Yoshida, H., Mori, K., Glimcher, L.H., Denko, N.C., Giaccia, A.J., et al. XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res. 2004, 64, 5943-5947.
15. Sato, A., Asano, T., Isono, M., Ito, K., Asano, T. Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells. BMC Urol. 2014, 14, 71.
16. Chen, Y., Tsai, Y.H., Tseng, S.H. RECK regulated endoplasmic reticulum stress response and enhanced cisplatin-induced cell death in neuroblastoma cells. Surgery 2013, 154, 968-979.
17. Hanke, N.T., Garland, L.L., Baker, A.F. Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines. J. Cancer Res. Clin. Oncol. 2016, 142, 549-560.
18. Baumeister, P., Dong, D., Fu, Y., Lee, A.S. Transcriptional induction of GRP78/BiP by histone deacetylase inhibitors and resistance to histone deacetylase inhibitor-induced apoptosis. Mol. Cancer Ther. 2009, 8, 1086-1094.
19. Rao, R., Fiskus, W., Ganguly, S., Kambhampati, S., Bhalla, K.N. HDAC inhibitors and chaperone function. Adv. Cancer Res. 2012, 116, 239-262.
20. Chen, Y.C., Huang, W.J., Hsu, J.L., Yu, C.C., Wang, W.T., Guh, J.H. A novel hydroxysuberamide derivative potentiates MG132-mediated anticancer activity against human hormone refractory prostate cancers—The role of histone deacetylase and endoplasmic reticulum stress. Prostate 2013, 73, 1270-1280.
21. Chiu, H.W., Yeh, Y.L., Wang, Y.C., Huang, W.J., Chen, Y.A., Chiou, Y.S., Ho, S.Y., Lin, P., Wang, Y.J. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo. PLoS ONE 2013, 8, e76340.
22. Choi, J.H., Lee, J.Y., Choi, A.Y., Hwang, K.Y., Choe, W., Yoon, K.S., Ha, J., Yeo, E.J., Kang, I. Apicidin induces endoplasmic reticulum stress-and mitochondrial dysfunction-associated apoptosis via phospholipase C1-and Ca2+-dependent pathway in mouse Neuro-2a neuroblastoma cells. Apoptosis 2012, 17, 1340-1358.
23. Hui, K.F., Chiang, A.K. Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism. Int. J. Cancer 2014, 135, 2950-2961.
24. Kikuchi, S., Suzuki, R., Ohguchi, H., Yoshida, Y., Lu, D., Cottini, F., Jakubikova, J., Bianchi, G., Harada, T., Gorgun, G., et al. Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma. Leukemia 2015, 29, 1918-1927.
25. Kim, S.M., Park, K.C., Jeon, J.Y., Kim, B.W., Kim, H.K., Chang, H.J., Choi, S.H., Park, C.S., Chang, H.S. Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer. BMC Cancer 2015, 15, 1003.
26. Liu, J., Edagawa, M., Goshima, H., Inoue, M., Yagita, H., Liu, Z., Kitajima, S. Role of ATF3 in synergistic cancer cell killing by a combination of HDAC inhibitors and agonistic anti-DR5 antibody through ER stress in human colon cancer cells. Biochem. Biophys. Res. Commun. 2014, 445, 320-326.
27. Rao, R., Nalluri, S., Kolhe, R., Yang, Y., Fiskus, W., Chen, J., Ha, K., Buckley, K.M., Balusu, R., Coothankandaswamy, V., et al. Treatment with panobinostat induces glucose-regulated protein 78 acetylation and endoplasmic reticulum stress in breast cancer cells. Mol. Cancer Ther. 2010, 9, 942-952.
28. Suzuki, M., Endo, M., Shinohara, F., Echigo, S., Rikiishi, H. Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells. Cancer Chemother. Pharmacol. 2009, 64, 1115-1122.
29. Chen, Y., Tseng, S.H. The potential of RECK inducers as antitumor agents for glioma. Anticancer Res. 2012, 32, 2991-2998.
30. Chen, Y., Tsai, Y.H., Tseng, S.H. Valproic acid affected the survival and invasiveness of human glioma cells through diverse mechanisms. J. Neurooncol. 2012, 109, 23-33.
31. Liu, L.T., Chang, H.C., Chiang, L.C., Hung, W.C. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res. 2003, 63, 3069-3072.
32. Clark, J.C., Thomas, D.M., Choong, P.F., Dass, C.R. RECK—A newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev. 2007, 26, 675-683.
33. Meng, N., Li, Y., Zhang, H., Sun, X.F. RECK, a novel matrix metalloproteinase regulator. Histol. Histopathol. 2008, 23, 1003-1010.
34. Noda, M., Takahashi, C. Recklessness as a hallmark of aggressive cancer. Cancer Sci. 2007, 98, 1659-1665.
35. Silveira Correa, T.C., Massaro, R.R., Brohem, C.A., Taboga, S.R., Lamers, M.L., Santos, M.F., Maria-Engler, S.S. RECK-mediated inhibition of glioma migration and invasion. J. Cell Biochem. 2010, 110, 52-61.
36. Silveira Correa, T.C., Brohem, C.A., Winnischofer, S.M.B., da Silva Cardeal, L.B., Sasahara, R.M., Taboga, S.R., Sogayar, M.C., Maria-Engler, S.S. Down-regulation of the RECK-tumor-and metastasis-suppressor gene in glioma invasiveness. J. Cell Biochem. 2006, 99, 156-167.
37. Namwat, N., Puetkasichonpasutha, J., Loilome, W., Yongvanit, P., Techasen, A., Puapairoj, A., Sripa, B., Tassaneeyakul, W., Khuntikeo, N., Wongkham, S. Downregulation of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) is associated with enhanced expression of matrix metalloproteinases and cholangiocarcinoma metastases. J. Gastroenterol. 2011, 46, 664-675.
38. Nagini, S. RECKing MMP: Relevance of reversion-inducing cysteine-rich protein with Kazal motifs as a prognostic marker and therapeutic target for cancer (a review). Anticancer Agents Med. Chem. 2012, 12, 718-725.
39. Chang, H.C., Liu, L.T., Hung, W.C. Involvement of histone deacetylase in RAS-induced down-regulation of the metastasis suppressor RECK. Cell Signal 2004, 16, 675-679.
40. Chang, H.C., Cho, C.Y., Hung, W.C. Silencing of the metastasis suppressor RECK by RAS oncogene is mediated by DNA methyltransferase 3b-induced promoter methylation. Cancer Res. 2006, 66, 8413-8420.
41. Hsu, M.C., Chang, H.C., Hung, W.C. HER-2/neu represses the metastasis suppressor RECK via ERK and Sp transcription factors to promote cell invasion. J. Biol. Chem. 2006, 281, 4718-4725.
42. Lee, K.J., Lee, K.Y., Lee, Y.M. Downregulation of a tumor suppressor RECK by hypoxia through recruitment of HDAC1 and HIF-1α to reverse HRE site in the promoter. Biochim. Biophys. Acta 2010, 1803, 608-616.
43. Yeh, H.H., Tseng, Y.F., Hsu, Y.C., Lan, S.H., Wu, S.Y., Raghavaraju, G., Cheng, D.E., Lee, Y.R., Chang, T.Y., Chow, N.H., et al. Ras induces experimental lung metastasis through up-regulation of RbAp46 to suppress RECK promoter activity. BMC Cancer 2015, 15, 172.
44. Somanna, N.K., Valente, A.J., Krenz, M., McDonald, K.S., Higashi, Y., Noda, M., Chandrasekar, B. Histone deacetyltransferase inhibitors Trichostatin A and Mocetinostat differentially regulate MMP9, IL-18 and RECK expression, and attenuate Angiotensin II-induced cardiac fibroblast migration and proliferation. Hypertens. Res. 2016, 39, 709-716.
45. Jeon, H.W., Lee, Y.M. Inhibition of histone deacetylase attenuates hypoxia-induced migration and invasion of cancer cells via the restoration of RECK expression. Mol. Cancer Ther. 2010, 9, 1361-1370.
46. Berezin, V., Walmod, P.S., Filippov, M., Dityatev, A. Targeting of ECM molecules and their metabolizing enzymes and receptors for the treatment of CNS diseases. Prog. Brain Res. 2014, 214, 353-388.
47. Ahn, M.Y., Kang, D.O., Na, Y.J., Yoon, S., Choi, W.S., Kang, K.W., Chung, H.Y., Jung, J.H., Kim, H.S. Histone deacetylase inhibitor, apicidin, inhibits human ovarian cancer cell migration via class II histone deacetylase 4 silencing. Cancer Lett. 2012, 325, 189-199.
48. Pan, Y., Wang, L., Kang, S.G., Lu, Y., Yang, Z., Huynh, T., Chen, C., Zhou, R., Guo, M., Zhao, Y. Gd-metallofullerenol nanomaterial suppresses pancreatic cancer metastasis by inhibiting the interaction of histone deacetylase 1 and metastasis-associated protein 1. ACS Nano 2015, 9, 6826-6836.
49. Bai, T., Dong, D.S., Pei, L. Synergistic antitumor activity of resveratrol and miR-200c in human lung cancer. Oncol. Rep. 2014, 31, 2293-2297.